Vaxcyte officer proposes $1.56M sale of 18,000 shares

Wassil's transaction history in the prior three months lists five sales dated August 3 through October 1, 2026.

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) officer James Wassil reported a proposed sale of 18,000 common shares through UBS Financial Services Inc., at an aggregate market value of $1,561,320.00 and an approximate sale date of October 5, 2026. The shares are listed as acquired from the issuer through exercise of a stock option, with cash as the payment method.

Key Figures

Proposed sale: 18,000 shares Aggregate market value: $1,561,320.00 Shares outstanding: 148,805,278 shares

3 metrics

Proposed sale 18,000 shares Common shares; approximate sale date October 5, 2026

Aggregate market value $1,561,320.00 Proposed sale

Shares outstanding 148,805,278 shares Issuer share count shown in the securities information

Key Terms

Rule 144, attorney-in-fact, Exercise of stock option

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

attorney-in-fact regulatory

"as attorney-in-fact for James Wassil"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Exercise of stock option financial

"Exercise of stock option"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares did James Wassil propose to sell?

James Wassil, an officer of Vaxcyte, reported a proposed sale of 18,000 common shares, with an aggregate market value of $1,561,320.00.

How did James Wassil acquire the PCVX shares listed for sale?

The shares are listed as acquired from Vaxcyte through exercise of a stock option, with cash as the payment method.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 04:10 PM Accepted by SEC EDGAR 10/05/2026 - 04:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	18000	1561320.00	148805278	10/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/05/2026	Exercise of stock option	Issuer			18000	10/05/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	10/01/2026	2250	127512.45
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	08/03/2026	2250	121194.45
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	09/01/2026	3477	212352.66
James Wassil 825 INDUSTRIAL ROAD STE. 300 SAN CARLOS CA 94070	Common	09/04/2026	1381	84462.51
James Wassil 825 INDUSTRIAL ROAD STE. 300 SAN CARLOS CA 94070	Common	09/09/2026	1334	79400.61

144: Remarks and Signature

Remarks
Date of Notice	10/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)